Sometimes, trying to find answers to Alzheimer’s disease feels like traveling through an endless tunnel.
The numbers speak for themselves: from 1988 to 2014, only four of 127 medicines investigated for the disease were approved by the U.S. Food and Drug Administration (FDA).1
But the scientists dedicated to ending Alzheimer’s have a way of seeing the light in the darkest of places; an ability to find the tiny pinpricks of hope, chipping away until things get clearer.
Shining a light on failure
The difficulties in creating a medicine to treat Alzheimer’s are as complex as the disease itself. Clinical trials face challenges in recruiting volunteers, and the intricacies of the brain make it difficult for treatments to cross the blood-brain barrier. Biomarkers, which help health care professionals identify the presence of disease, are not currently validated for Alzheimer’s disease, although several are being researched.2
Jim Summers, Ph.D., vice president, discovery neuroscience research at AbbVie, explains, “What we know now is that the disease (Alzheimer’s) is brewing for decades before people are symptomatic, and we are trying to find ways to treat it earlier. If you have high cholesterol, for example, you don’t wait to treat it until the patient has a heart attack.”
Randall Bateman, M.D., the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine in St. Louis, Missouri, and scientific co-founder of C2N Diagnostics, points to an additional cause of Alzheimer’s trial failures.
“Imagine trying to find a drug that could truly change the disease course. The odds that the drug would have benefit are greatly increased if you can demonstrate the drug does what it is designed to do. Without that information, you’re running a trial blind,” Bateman says. “If we can understand how to measure the disease process using biomarkers, the odds of (clinical trial) success are much higher.”
Could biomarkers hold the key to turn on the lights?
Bateman and his team at Washington University developed the stable isotope labeling kinetics (SILK™) platform to track the kinetics of two biomarkers, associated with Alzheimer’s disease – tau and beta amyloid. C2N Diagnostics, co-founded by Bateman and Dr. David Holtzman, the Andrew B. and Gretchen P. Jones Professor of Neurology and head of Washington University’s Department of Neurology, has refined these SILK™ biomarkers to test a given drug’s effect on how well these proteins are produced and cleared away.
By using SILK™ technology in Alzheimer’s research, scientists can better understand how the potential biomarkers build up and may be cleared from the body.
“Measuring the speed of protein changes can indicate what may happen in a drug trial. SILK™ provides a measure of the speed at which targets are affected and if the compound can normalize the abnormal protein metabolism. By measuring how much the proteins are normalized, we can then estimate the drug doses that are most likely to be successful,” Bateman explains.